Bulletin of the Korean Chemical Society

  • 제30권1호
  • /
  • Pages.77-82
  • /
  • 2009
  • /
  • 0253-2964(pISSN)
  • /
  • 1229-5949(eISSN)
대한화학회 (Korean Chemical Society)
권호 표지
DOI QR코드

DOI QR Code

Detecting Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) and Inactivated TAFIa (TAFIai) in Normal and Hemophilia A Plasmas

  • Hulme, John P. (Kyungwon University, Department of Bionano Technology) ;
  • An, Seong Soo A. (Kyungwon University, Department of Bionano Technology)
  • 발행 : 2009.01.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Thrombin activatable fibrinolysis inhibitor (TAFI) also known as plasma procarboxypeptidase B or U is a 60 kD glycoprotein, which is the major modulator of fibrinolysis in plasma. TAFI is a proenzyme, which is activated by proteolytic cleavage to an active carboxypeptidase B-like enzyme (TAFIa, 35.8 kD) by thrombin/thrombomodulin and plasmin. Modulation of fibrinolysis occurs when TAFIa enzymatically removes C-terminal lysine residues of partially degraded fibrin, thereby inhibiting the stimulation of tissue plasminogen activator (t-PA) modulated plasminogen activation. TAFIa undergoes a rapid conformational change at $37{^{\circ}C}$ to an inactive isoform called TAFIai. Potato tuber carboxypetidase inhibitor (PTCI) was shown to specifically bind to TAFIa as well as TAFIai. In this study, a novel immunoassay TAFIa/ai ELISA was used for quantitation of the two TAFI activation isoforms TAFIa and TAFIai. The ELISA utilizes PTCI as the capture agent and a double antibody sandwich technique for the detection. Low levels of TAFIa/ai antigen levels were detected in normal plasma and elevated levels were found in hemophilia A plasmas. TAFIa/ai antigen represents a novel marker to monitor fibrinolysis and TAFIa/ai ELISA may be a valuable assay for studying the role of TAFI in normal hemostasis and in pathological conditions.

키워드

참고문헌

  1. Redlitz, A.; Tan, A. K.; Eaton, D. L.; Plow, E. F. J. Clin. Invest. 1995, 96, 2534 https://doi.org/10.1172/JCI118315
  2. Bajzar, L.; Manuel, R.; Neisheim, M. E. J. Biol. Chem. 1995, 270, 1477
  3. Bajzar, L.; Morser, J.; Neisheim, M. E. J. Biol. Chem. 1996, 271, 16603 https://doi.org/10.1074/jbc.271.28.16603
  4. Sakharov, D. V.; Plow, E. F.; Rijken, D. C. J. Biol. Chem. 1997, 272, 14477 https://doi.org/10.1074/jbc.272.22.14477
  5. Wang, W.; Boffa, M. B.; Bajzar, L.; Walker, J. B.; Neisheim, M. E. J. Biol. Chem. 1998, 273, 27176 https://doi.org/10.1074/jbc.273.42.27176
  6. Hendriks, D.; Wang, W.; Scharpe, S.; Lommaert, M. P.; van Sande, M. Biochim. Biophys. Acta 1990, 1034, 86 https://doi.org/10.1016/0304-4165(90)90157-R
  7. Marx, P. F.; Dawson, P. E.; Bouma, B. N.; Meijers, J. C. Biochemistry 2002, 41, 6688 https://doi.org/10.1021/bi015982e
  8. Marx, P. F.; Hackeng, T. M.; Dawson, P. E.; Griffin, J. H.; Meijers, J. C.; Bouma, B. N. J. Biol. Chem. 2000, 275, 12410 https://doi.org/10.1074/jbc.275.17.12410
  9. Franco, R. F.; Fagundes, M. G.; Meijers, J. C.; Reitsma, P. H.; Lourenco, D.; Morelli, V.; Maffei, F. H.; Ferrari, I. C.; Piccinato, C. E.; Silva, W. A. Jr.; Zago, M. A. Haematologica. 2001, 86, 510
  10. Henry, M.; Aubert, H.; Morange, P. E.; Nanni, I.; Alessi, M. C.; Tiret, L.; Juhan-Vague, I. Blood 2001, 97, 2053 https://doi.org/10.1182/blood.V97.7.2053
  11. Kostka, H.; Kuhlisch, E.; Schellong, S.; Siegert, G. Clin Lab. 2003, 49, 645
  12. Stromqvist, M.; Schatteman, K.; Leurs, J.; Verkerk, R.; Andersson, J. O.; Johansson, T.; Scharpe, S.; Hendriks, D. Thromb Haemost. 2001, 85, 12
  13. Van Thiel, D. H.; George, M.; Fareed, J. Thromb Haemost. 2001, 85, 667
  14. Meijers, J. C.; Oudijk, E. J. D.; Mosnier, L. O.; Bos, R.; Bouma, B. N.; Nieuwenhuis, H. K.; Fijnheer, R. Br. J. Haematol. 2000, 108, 518 https://doi.org/10.1046/j.1365-2141.2000.01890.x
  15. Watanabe, R.; Wada, H.; Watanabe, Y.; Sakakura, M.; Nakasaki, T.; Mori, Y.; Nishikawa, M.; Gabazza, E. C.; Nobori, T.; Shiku, H. Thromb Res. 2001, 104, 1 https://doi.org/10.1016/S0049-3848(01)00331-0
  16. Silveira, A.; Schatteman, K.; Goossens, F.; Moor, E.; Scharpe, S.; Stromqvist, M.; Hendriks, D.; Hamsten, A. Thromb Haemost. 2000, 84, 364
  17. van Tilburg, N. H.; Rosendaal, F. R.; Bertina, R. M. Blood 2000, 95, 2855
  18. Schatteman, K. A.; Goossens, F. J; Leurs, J.; Kasahara, Y.; Scharpe, S. S.; Hendriks, D. F. Clin. Chem. Lab Med. 2001, 39, 806 https://doi.org/10.1515/CCLM.2001.133
  19. Schneider, M.; Boffa, M.; Stewart, R.; Rahman, M.; Koschinsky, M.; Nesheim, M. J. Biol. Chem. 2002, 277, 1021 https://doi.org/10.1074/jbc.M104444200
  20. Gils, A.; Alessi, M. C.; Brouwers, E.; Peeters, M.; Marx, P.; Leurs, J.; Bouma, B.; Hendriks, D.; Juhan-Vague, I.; Declerck, P. J. Arterioscler Thromb Vasc Biol. 2003, 23, 1122 https://doi.org/10.1161/01.ATV.0000074145.58172.BD
  21. Knoefler, R.; Ludwig, K.; Kostka, H.; Kuhlisch, E.; Siegert, G.; Suttorp, M. Semin Thromb Hemost. 2003, 29, 575 https://doi.org/10.1055/s-2004-815625
  22. Guimaraes, A. H.; van Tilburg, N. H.; Vos, H. L.; Bertina, R. M.; Rijken, D. C. Br. J. Haematol. 2004, 124, 659 https://doi.org/10.1111/j.1365-2141.2004.04824.x
  23. Tani, S.; Akatsu, H.; Ishikawa, Y.; Okada, N.; Okada, H. Microbiol Immunol. 2003, 47, 295 https://doi.org/10.1111/j.1348-0421.2003.tb03398.x
  24. Schatteman, K. A.; Goosens, F. J.; Scharpe, S. S.; Neels, H. M.; Hendriks, D. F. Clin. Chem. 1999, 45, 807
  25. Lwaleed, B. A.; Goyal, A.; Greenfield, R. S.; Cooper, A. J. Blood Coagul. Fibrinolysis 2007, 18, 449 https://doi.org/10.1097/MBC.0b013e328136c18a
  26. Grunewald, M.; Siegemund, A.; Grunewald, A.; Konegan, A.; Koksch, M.; Griesshammer, M. Haemophilia 2002, 8, 768 https://doi.org/10.1046/j.1365-2516.2002.00686.x
  27. Mosnier, L. O.; Lisman, T.; van den Berg, H. M.; Nieuwenhuis, H. K.; Meijers, J. C.; Bouma, B. N. Thromb Haemost. 2001, 86, 1035
  28. Neill, E. K.; Stewart, R. J.; Schneider, M. M.; Nesheim, M. E. Anal. Biochem. 2004, 330, 332 https://doi.org/10.1016/j.ab.2004.04.007
  29. Antovic, J.; Schulman, S.; Eelde, A.; Blomback, M. Haemophilia 2001, 7, 557 https://doi.org/10.1046/j.1365-2516.2001.00571.x
  30. Greenfield, R. S.; Antovic, J.; An, J.; Blombeck, M.; An, S. S. A. Proceedings of the 16th Int'l Congress Fibrinolysis and Proteolysis 2002; Abstr. S49

피인용 문헌

  1. Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis vol.45, pp.4, 2010, https://doi.org/10.5045/kjh.2010.45.4.264
  2. Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis vol.17, pp.6, 2009, https://doi.org/10.1111/jth.14432
  3. Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery? vol.22, pp.2, 2021, https://doi.org/10.3390/ijms22020883
  4. Endogenous fibrinolysis inhibitors in acute coronary syndrome vol.10, pp.None, 2021, https://doi.org/10.1016/j.ahjo.2021.100058